Patents by Inventor William E. Yelle
William E. Yelle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7098224Abstract: Methods and compositions are disclosed utilizing hydroxylansoprazole for the treatment of ulcers in humans. Hydroxylansoprazole exhibits a lessened liability toward drug-drug interactions than lansoprazole and a more predictable dosing regimen than lansoprazole. Hydroxylansoprazole is also useful for the treatment of gastroesophageal reflux and other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.Type: GrantFiled: October 14, 2003Date of Patent: August 29, 2006Assignee: Sepracor Inc.Inventor: William E. Yelle
-
Patent number: 7030142Abstract: The invention relates to novel methods using, and pharmaceutical compositions comprising, ziprasidone metabolites. The methods and compositions of the invention are suitable for the treatment of neuroleptic and related disorders. The invention further encompasses methods of preparing ziprasidone sulfoxide and ziprasidone sulfone.Type: GrantFiled: March 17, 2000Date of Patent: April 18, 2006Assignee: Sepracor Inc.Inventors: Timothy J. Barberich, Paul D. Rubin, William E. Yelle
-
Publication number: 20040266792Abstract: Methods and compositions utilizing compounds represented by Formula III, 1Type: ApplicationFiled: July 13, 2004Publication date: December 30, 2004Applicant: Sepracor Inc.Inventor: William E. Yelle
-
Publication number: 20040224989Abstract: Methods and compositions are disclosed utilizing optically pure (−) lansoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of lansoprazole. The optically pure (−) isomer is also-useful for the treatment of gastroesophageal reflux. (−) Lansoprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.Type: ApplicationFiled: June 8, 2004Publication date: November 11, 2004Inventors: Timothy J. Barberich, William E. Yelle, Paul D. Rubin
-
Publication number: 20040171647Abstract: Methods and compositions are disclosed utilizing optically pure S(−)rabeprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of rabeprazole. The optically pure S(−) isomer is also useful for the treatment of gastroesophageal reflux. S(−)rabeprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.Type: ApplicationFiled: March 8, 2004Publication date: September 2, 2004Applicant: Sepracor Inc.Inventors: Patrick Koch, Paul D. Rubin, William E. Yelle
-
Publication number: 20040077688Abstract: Methods and compositions are disclosed utilizing hydroxylansoprazole for the treatment of ulcers in humans. Hydroxylansoprazole exhibits a lessened liability toward drug-drug interactions than lansoprazole and a more predictable dosing regimen than lansoprazole. Hydroxylansoprazole is also useful for the treatment of gastroesophageal reflux and other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.Type: ApplicationFiled: October 14, 2003Publication date: April 22, 2004Applicant: SEPRACOR INC.Inventor: William E. Yelle
-
Publication number: 20030069280Abstract: Methods and compositions are disclosed utilizing optically pure S(−)rabeprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of rabeprazole. The optically pure S(−) isomer is also useful for the treatment of gastroesophageal reflux. S(−)rabeprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.Type: ApplicationFiled: October 2, 2002Publication date: April 10, 2003Applicant: SEPRACOR INC.Inventors: Patrick Koch, Paul D. Rubin, William E. Yelle
-
Publication number: 20030008903Abstract: Methods and compositions are disclosed utilizing optically pure (+) lansoprazole for the treatment of S ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of lansoprazole. The optically pure (+) isomer is also useful for the treatment of gastroesophageal reflux. (+) Lansoprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.Type: ApplicationFiled: August 12, 2002Publication date: January 9, 2003Applicant: Sepracor Inc.Inventors: Timothy J. Barberich, William E. Yelle, Paul D. Rubin
-
Patent number: 6500833Abstract: Methods and compositions utilizing a compound represented by Formula III, wherein R is chosen from —OH, —P(O)(OH)2 and —SO3H, or pharmaceutically acceptable salts thereof, for the treatment of psychoses in humans are disclosed. The compounds of the present invention exhibit fewer side effects than risperidone, a lessened liability toward drug-drug interactions than risperidone and a more predictable dosing regimen than risperidone. The compounds of the invention are also useful for the treatment of emesis and withdrawal syndromes.Type: GrantFiled: November 17, 2000Date of Patent: December 31, 2002Assignee: Sepracor Inc.Inventor: William E. Yelle
-
Patent number: 6498171Abstract: Methods and compositions are disclosed utilizing hydroxyomeprazole for the treatment of ulcers in humans. Hydroxyomeprazole exhibits a lessened liability toward drug-drug interactions than omeprazole and a more predictable dosing regimen than omeprazole. Hydroxyomeprazole is also useful for the treatment of gastroesophageal reflux and other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.Type: GrantFiled: August 10, 2001Date of Patent: December 24, 2002Assignee: Sepracor Inc.Inventors: William E. Yelle, Dean A. Handley
-
Patent number: 6468997Abstract: Methods and compositions are disclosed utilizing N-desmethylolanzapine for the treatment of psychosis in humans. N-Desmethylolanzapine exhibits a lessened liability toward drug-drug interactions than olanzapine and a more predictable dosing regimen than olanzapine. N-Desmethylolanzapine is also useful for the treatment of acute mania, mild anxiety states, anxiety disorders, schizophrenia, bipolar disorder, attention deficit hyperactivity disorder, autistic disorder, excessive aggression, substance abuse, depressive signs and symptoms, tic disorder, functional bowel disorder and fungal dermatitis.Type: GrantFiled: December 19, 2001Date of Patent: October 22, 2002Assignee: Sepracor Inc.Inventor: William E. Yelle
-
Patent number: 6465469Abstract: The S-isomer of the hydroxy metabolite of nefazodone, S-hydroxynefazodone, is an effective treatment for depression which does not give rise to the adverse effects associated with nefazodone. S-hydroxynefazodone is also useful in the treatment of migraine headaches, panic disorders, post traumatic stress disorder and sleep disorders.Type: GrantFiled: April 7, 2000Date of Patent: October 15, 2002Assignee: Sepracor Inc.Inventors: Timothy J. Barberich, Paul D. Rubin, William E. Yelle
-
Patent number: 6465470Abstract: The R-isomer of the hydroxy metabolite of nefazodone, R-hydroxynefazodone, is an effective treatment for depression which does not give rise to the adverse effects associated with nefazodone. R-hydroxynefazodone is also useful in the treatment of migraine headaches, panic disorders, post traumatic stress disorder and sleep disorders.Type: GrantFiled: November 19, 2001Date of Patent: October 15, 2002Assignee: Sepracor Inc.Inventors: Timothy J. Barberich, Paul D. Rubin, William E. Yelle
-
Publication number: 20020115691Abstract: Methods and compositions are disclosed utilizing optically pure (−) rabeprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of rabeprazole. The optically pure (−) isomer is also useful for the treatment of gastroesophageal reflux. (−) Rabeprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.Type: ApplicationFiled: February 25, 2002Publication date: August 22, 2002Applicant: SEPRACOR INC.Inventors: Patrick Koch, Paul D. Rubin, William E. Yelle
-
Publication number: 20020099079Abstract: Methods and compositions are disclosed utilizing hydroxylansoprazole for the treatment of ulcers in humans. Hydroxylansoprazole exhibits a lessened liability toward drug-drug interactions than lansoprazole and a more predictable dosing regimen than lansoprazole. Hydroxylansoprazole is also useful for the treatment of gastroesophageal reflux and other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.Type: ApplicationFiled: October 19, 2001Publication date: July 25, 2002Applicant: SEPRACOR INC.Inventor: William E. Yelle
-
Publication number: 20020082245Abstract: Methods and compositions utilizing compounds represented by Formula III, 1Type: ApplicationFiled: December 10, 2001Publication date: June 27, 2002Applicant: Sepracor Inc.Inventor: William E. Yelle
-
Publication number: 20020082251Abstract: Methods and compositions are disclosed utilizing N-desmethylolanzapine for the treatment of psychosis in humans. N-Desmethylolanzapine exhibits a lessened liability toward drug-drug interactions than olanzapine and a more predictable dosing regimen than olanzapine. N-Desmethylolanzapine is also useful for the treatment of acute mania, mild anxiety states, anxiety disorders, schizophrenia, bipolar disorder, attention deficit hyperactivity disorder, autistic disorder, excessive aggression, substance abuse, depressive signs and symptoms, tic disorder, functional bowel disorder and fungal dermatitis.Type: ApplicationFiled: December 19, 2001Publication date: June 27, 2002Applicant: SEPRACOR INC.Inventor: William E. Yelle
-
Publication number: 20020065272Abstract: Methods and compositions are disclosed utilizing olanzapine-N-oxide for the treatment of psychosis in humans. Olanzapine-N-oxide exhibits a lessened liability toward drug-drug interactions than olanzapine and a more predictable dosing regimen than olanzapine. Olanzapine-N-oxide is also useful for the treatment of acute mania, mild anxiety states, anxiety disorders, schizophrenia, bipolar disorder, attention deficit hyperactivity disorder, autistic disorder, excessive aggression, substance abuse, depressive signs and symptoms, tic disorder, functional bowel disorder and fungal dermatitis.Type: ApplicationFiled: October 30, 2001Publication date: May 30, 2002Applicant: SEPRACOR INC.Inventor: William E. Yelle
-
Patent number: 6384037Abstract: The R-isomer of the hydroxy metabolite of nefazodone, R-hydroxynefazodone, is an effective treatment for depression which does not give rise to the adverse effects associated with nefazodone. R-hydroxynefazodone is also useful in the treatment of migraine headaches, panic disorders, post traumatic stress disorder and sleep disorders.Type: GrantFiled: April 7, 2000Date of Patent: May 7, 2002Assignee: Sepracor Inc.Inventors: Timothy J. Barberich, Paul D. Rubin, William E. Yelle
-
Publication number: 20020052382Abstract: The R-isomer of the hydroxy metabolite of nefazodone, R-hydroxynefazodone, is an effective treatment for depression which does not give rise to the adverse effects associated with nefazodone. R-hydroxynefazodone is also useful in the treatment of migraine headaches, panic disorders, post traumatic stress disorder and sleep disorders.Type: ApplicationFiled: November 19, 2001Publication date: May 2, 2002Applicant: Sepracor Inc.Inventors: Timothy J. Barberich, Paul D. Rubin, William E. Yelle